QPPV.COM KNOWLEDGE ASSESSMENT

Medical Literature Monitoring in Pharmacovigilance: Knowledge Assessment

Test your understanding of the concepts covered by Medical Literature Monitoring in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most defensible interpretation of the statement that MLM cases may be downloaded from EudraVigilance?

Downloading a case is an administrative activity with no need for further assessment Downloaded cases may support case management, signal detection and aggregate activities, so procedures should define how they are handled Only the EMA may use the cases for any pharmacovigilance purpose Downloaded cases automatically become confirmed adverse reactions for all MAH products

Question 2 of 10 Why should downloaded MLM cases be medically reviewed even when they originated from an EMA process?

The MAH may need to assess product relevance, reportability, duplication, additional information and signal significance EMA cases are not subject to any data-quality standards The MAH must always submit an identical second case to EudraVigilance Medical review is required only to determine whether the publication is copyrighted

Question 3 of 10 Which operational approach best supports timely and consistent management of downloaded MLM cases?

Allow each reviewer to use an undocumented process based on personal judgment Use scheduled downloads, standard filters, assigned reviewers, reason codes and KPI tracking Review only cases that appear medically serious at first glance Rely on the vendor’s records without reconciling them to company systems

Question 4 of 10 An MAH downloads an MLM-derived case that appears already to be present in its safety database and linked to the EMA EudraVigilance case. What is the most appropriate initial action?

Create a second case automatically to ensure the publication is represented twice Delete the existing case and replace it with the downloaded case Perform and document a deduplication assessment and retain the rationale for the handling decision Ignore the download because EMA cases are outside MAH procedures

Question 5 of 10 What is the best reason to track metrics such as time from download to screening and time from review to escalation?

Metrics demonstrate that every case is medically serious Metrics help monitor timeliness, process performance and potential compliance risks Metrics replace the need for case-level documentation Metrics determine whether a publication is scientifically valid

Question 6 of 10 Which statement best describes the inspection significance of an MLM binder or equivalent curated evidence set?

It replaces the underlying controlled records and procedures It facilitates retrieval of current scope, procedures, operational evidence and escalation records It is required only for companies that do not use EudraVigilance It should contain only publications judged to be safety signals

Question 7 of 10 An MAH discovers that one of its active substances is included in the EMA MLM programme. Which conclusion is most appropriate?

The MAH can discontinue all literature surveillance for products containing that substance The MAH must determine the programme boundaries and identify any residual monitoring obligations The MAH is no longer responsible for reviewing MLM cases in EudraVigilance The MAH only needs to monitor literature if the EMA requests a follow-up

Question 8 of 10 Which sequence best represents the central EMA MLM process described in the article?

MAH identifies a publication, submits a signal to EVDAS, and EMA confirms the case EMA reviews designated publications, extracts relevant information, creates an ICSR and submits it to EudraVigilance EudraVigilance searches journals automatically, and the QPPV approves every resulting case EVDAS creates an ICSR, which is then transferred to the EMA literature archive

Question 9 of 10 Which regulatory pairing is most accurate for the activities described in the article?

GVP Module I addresses system and QPPV oversight, Module VI addresses collection and reporting, and Module IX addresses signal management GVP Module I addresses only journal selection, Module VI addresses inspections, and Module IX addresses QPPV appointment GVP Module VI addresses only clinical trials, while Module IX governs copyright retention Commission Implementing Regulation (EU) No 520/2012 replaces all GVP requirements for literature cases

Question 10 of 10 Which responsibility allocation is most consistent with the SOP model described in the article?

The QPPV performs downloads, while QA decides whether a case is reportable The EV administrator performs scheduled downloads, the medical reviewer assesses cases, and the signal lead coordinates signal evaluation The vendor alone decides signal escalation without MAH oversight The medical reviewer approves the pharmacovigilance system and the QPPV performs database administration

Medical Literature Monitoring in Pharmacovigilance: Knowledge Assessment

Cookie Settings